Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

JAK inhibitors and infections risk: focus on herpes zoster
Flavia Sunzini, Iain B. McInnes, Stefan Siebert
Therapeutic Advances in Musculoskeletal Disease (2020) Vol. 12
Open Access | Times Cited: 102

Showing 26-50 of 102 citing articles:

Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials
Yoshiya Tanaka, Arthur Kavanaugh, Jason Wicklund, et al.
Modern Rheumatology (2021) Vol. 32, Iss. 1, pp. 1-11
Open Access | Times Cited: 37
Polymer nanotherapeutics: A versatile platform for effective rheumatoid arthritis therapy
Rimsha Nooreen, Shweta Nene, Harsha Jain, et al.
Journal of Controlled Release (2022) Vol. 348, pp. 397-419
Closed Access | Times Cited: 28
JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum
Luiz Guilherme M Castro
International Journal of Dermatology (2023) Vol. 62, Iss. 8, pp. 1088-1093
Closed Access | Times Cited: 15
Incidence of Herpes Zoster in Patients With Rheumatoid Arthritis in the United States: A Retrospective Cohort Study
David Singer, Philippe Thompson‐Leduc, Sara Poston, et al.
The Journal of Rheumatology (2023) Vol. 50, Iss. 7, pp. 873-880
Open Access | Times Cited: 14
Macrophage re-programming by JAK inhibitors relies on MAFB
Baltasar López-Navarro, Miriam Simón‐Fuentes, Israel Ríos, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 6
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study
Roy Fleischmann, Jerzy Świerkot, Sara K. Penn, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e004007-e004007
Open Access | Times Cited: 6
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses
Oliver FitzGerald, Dafna D. Gladman, Philip J. Mease, et al.
Arthritis & Rheumatology (2024) Vol. 76, Iss. 9, pp. 1397-1407
Open Access | Times Cited: 5
Withania somnifera (L.) Dunal (Ashwagandha) for the possible therapeutics and clinical management of SARS-CoV-2 infection: Plant-based drug discovery and targeted therapy
Manali Singh, Kuldeep Jayant, Dipti Singh, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 22
Methotrexate in early rheumatoid arthritis: Is the anchor drug still holding?
Alessandro Giollo, Enrico Fuzzi, Andrea Doria
Autoimmunity Reviews (2022) Vol. 21, Iss. 4, pp. 103031-103031
Closed Access | Times Cited: 20
The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19
Peter J. Richardson, Bruce Robinson, Daniel P. Smith, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 951-951
Open Access | Times Cited: 20
Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors
Hanna Källmark, Tomas Bergström, Johanna Nagel, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 7, pp. 2024-2033
Open Access | Times Cited: 11
Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective
Shubhra Mishra, Anuraag Jena, Rinkal Kakadiya, et al.
Expert Review of Gastroenterology & Hepatology (2022) Vol. 16, Iss. 8, pp. 737-752
Closed Access | Times Cited: 18
Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance
Michiaki Takagi, Tatsuya Atsumi, Hiroaki Matsuno, et al.
Modern Rheumatology (2022) Vol. 33, Iss. 4, pp. 647-656
Closed Access | Times Cited: 18
Correlation between Type I Interferon Associated Factors and COVID-19 Severity
Dóra Bencze, Tünde Fekete, Kitti Pázmándi
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10968-10968
Open Access | Times Cited: 18
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis
Laura Calabrese, Andrea Chiricozzi, Clara De Simone, et al.
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 5, pp. 347-355
Open Access | Times Cited: 17
A real‐world Australian experience of upadacitinib for the treatment of severe atopic dermatitis
Vanessa Tran, Gayle Ross
Australasian Journal of Dermatology (2023) Vol. 64, Iss. 4
Closed Access | Times Cited: 10
Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Brett Hauber, Chiara Whichello, Jonathan Mauer, et al.
The Journal of Dermatology (2025)
Open Access
Disseminated Chickenpox Following Live Varicella Vaccination in a Crohn’s Disease Patient on Combination Immunosuppression
Quintin P. Solano, Sarah Uttal, Peter Higgins, et al.
Case Reports in Gastrointestinal Medicine (2025) Vol. 2025, Iss. 1
Open Access
Prevalence and incidence of comorbidities in patients with atopic dermatitis, psoriasis, alopecia areata, and vitiligo using a Japanese claims database
Yue Ma, Motohiko Chachin, Tomohiro Hirose, et al.
The Journal of Dermatology (2025)
Open Access
Hijacking JAKis: JAK inhibitors as potential antiviral molecules, a mini review
Claudie Eber, Éloi R. Verrier
Antiviral Research (2025), pp. 106153-106153
Closed Access
Upadacitinib Drug Survival in the Management of Patients With Moderate to Severe Atopic Dermatitis: Real‐Time Data From the Biogrid Database Registry
Nadine Abu‐Ghazaleh, Gayle Ross, Vanessa Morgan
Australasian Journal of Dermatology (2025)
Closed Access
Disseminated Varicella-Zoster Virus-Associated Acute Retinal Necrosis in a Post-Bone Marrow Transplant Patient
Sai Bhakti Mishra, Ankush Kawali, Padmamalini Mahendradas, et al.
Ocular Immunology and Inflammation (2025), pp. 1-3
Closed Access
A translational approach to improve therapeutics in atopic dermatitis and beyond
Daniel Liu, Dev Patel, Megan Lau, et al.
The Journal of Immunology (2025)
Closed Access
Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
Sissel Brandt Toft Sørensen, Prethibha George, Oladayo Jagun, et al.
Acta Dermato Venereologica (2025) Vol. 105, pp. adv42646-adv42646
Open Access
Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?
Chrysoula G. Gialouri, Gerasimos Evangelatos, G. Fragoulis
Mediterranean Journal of Rheumatology (2022) Vol. 33, Iss. Suppl 1, pp. 150-150
Open Access | Times Cited: 15

Scroll to top